Analytical Services Center for Medications Development Program

On July 17, 2022, the National Institute on Drug Abuse under the Department of Health and Human Services awarded Contract No. 75N98026D00031 to MRIGlobal to establish and operate the Analytical Services Center for Medications Development. This award, made in response to Solicitation 75N95024R00032, is not a request for quotes or proposals but a formal notice of contract issuance. The contract will be executed over a five-year period through the issuance of task orders and will utilize a hybrid funding structure combining Cost Plus Fixed Fee and Firm Fixed Price mechanisms to support the full scope of analytical services required. The primary place of performance is in Bethesda, Maryland, with all activities centered around advancing medications development through rigorous analytical support. The contract is managed by the National Institutes of Health’s NIDA office located at 9800 Medical Center Drive, Bethesda, MD, 20892. Primary point of contact is Shaun Rostad, reachable at 301-594-9516 or shaun.rostad@nih.gov, with secondary support provided by Josh Lazarus at 301-827-6923 or josh.lazarus@nih.gov. The North American Industry Classification System code for this contract is 541715, indicating the nature of the work as research and development in the physical, engineering, and life sciences. The contract was posted on SAM.gov on July 17, 2026, and all performance, reporting, and administrative functions are to be conducted in alignment with federal acquisition regulations and NIDA-specific program objectives.